Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Under Investigation By Oregon For Deceptive Promotions

This article was originally published in The Pink Sheet Daily

Executive Summary

State effort is focused on one unnamed drug but may expand; the company is already facing a federal inquiry about off-label promotion of Botox for headache treatment.
Advertisement

Related Content

FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement
FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement
Beauty Is A Pain: FDA Cites Latisse Web Site For Implying Drug Is A Cosmetic
Bayer Loses Oversight Of Yaz DTC Ads Under Agreement With States Attorneys General
Pfizer Forks Over $894 Million To Settle Celebrex/Bextra Litigation
Pfizer Forks Over $894 Million To Settle Celebrex/Bextra Litigation

Topics

Advertisement
UsernamePublicRestriction

Register

PS068697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel